Last close As at 05/08/2026
GBP0.01
— 0.00 (0.00%)
Market capitalisation
GBP21m
Research: Industrials
Quadrise has entered into an agreement with an international chemicals and mining group headquartered in Morocco. During calendar Q120 the two parties will work together on a project to carry out a trial of MSAR, Quadrise’s synthetic enhanced heavy fuel oil, on a pilot plant test facility located at one of the client’s sites in Morocco. If successful, Quadrise will then undertake feasibility studies in preparation for commercial-scale trials on an industrial unit and a steam boiler owned and operated by the client. These potential trials would be covered by new agreements.
Written by
Quadrise Fuels International International |
Initial pilot trial in Morocco |
Material transfer and cooperation agreement |
Alternative energy |
29 November 2019 |
Share price performance
Business description
Analyst
Quadrise Fuels International is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||
Quadrise has entered into an agreement with an international chemicals and mining group headquartered in Morocco. During calendar Q120 the two parties will work together on a project to carry out a trial of MSAR, Quadrise’s synthetic enhanced heavy fuel oil, on a pilot plant test facility located at one of the client’s sites in Morocco. If successful, Quadrise will then undertake feasibility studies in preparation for commercial-scale trials on an industrial unit and a steam boiler owned and operated by the client. These potential trials would be covered by new agreements.
Year end |
Revenue |
EBITDA |
PBT* |
EPS* |
DPS |
P/E |
06/16 |
0.0 |
(4.0) |
(4.1) |
(0.49) |
0.0 |
N/A |
06/17 |
0.1 |
(3.9) |
(4.1) |
(0.45) |
0.0 |
N/A |
06/18 |
0.0 |
(3.3) |
(3.5) |
(0.37) |
0.0 |
N/A |
06/19 |
0.0 |
(2.8) |
(3.0) |
(0.32) |
0.0 |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
The cost of the initial trial is estimated at £16k, to be shared equally between Quadrise and the client, with Quadrise providing MSAR fuel, related equipment and engineering services to support this initial test phase. Quadrise will submit a written report to the client when the test phase has been completed. Assuming that this first phase is successful, the client will pay Quadrise £100k for the feasibility and engineering studies for commercial-scale trials, payable in stages on reaching agreed milestones.
Quadrise’s representative in Morocco, Younes Maamar, is the former CEO of the Moroccan state electricity company and was instrumental in securing this agreement. Under the terms of his agreement with Quadrise announced in March 2019, Quadrise will issue Younes Maamar with 3m warrants, exercisable at any time until 6 March 2022 and at a price equal to the average mid-market closing price over the five days ending on and including 29 November 2019.
The news demonstrates that management’s policy of incentivising local distributors with warrants is resulting in meaningful projects. Moreover, it indicates the potential for wider interest in MSAR for industrial applications as well as in the marine bunker fuel and power generation sectors.
|
|
Research: Healthcare
Hutchison China MediTech (HCM) has announced that Elunate (fruquintinib capsules) have been included in China’s National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA). Although expected, this is a huge positive as from 1 January 2020 Elunate will be available in all state-run hospital pharmacies and patients on NHSA insurance schemes will be reimbursed. HCM’s innovative oncology assets are making significant progress in China. It has now submitted the China NDA for surufatinib for treating non-pancreatic NET tumours, a large unmet clinical need. Surufatinib is likely to be the first of HCM’s non-partnered assets to reach the China market (late 2020). We value HCM at $5.7bn.